Initiate proof-of-concept trial in X-ALD patients
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 17 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Expect to Initiate Proof-of-Concept Trial in X-ALD Patients Mid-2021”
What we found
Evidence strength A What the grades mean
Later 10-Q filings state the Phase 1b X-ALD trial was initiated in June 2021, within the mid-2021 deadline window.
-
A Viking Therapeutics, Inc. 8-K filed 2021-07-28
“Phase 1b proof-of-concept trial in X-ALD patients underway.” ✓ confirmed on the page
-
A Viking Therapeutics, Inc. 10-Q filed 2021-07-28
“In June 2021, we initiated a Phase 1b clinical trial of VK0214 in patients with X-ALD.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Proof-of-concept trial in X-ALD patients
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Viking Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-VKTX-024053 · Corrections policy